Real‐life experience in switching to new extended half‐life products at European haemophilia centres-Reference-Cited by-同舟云学术

Real‐life experience in switching to new extended half‐life products at European haemophilia centres

Published:2019-08-16 Issue:6 Volume:25 Page:946-952
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Peyvandi Flora¹²^ORCID,Garagiola Isabella¹^ORCID,Boscarino Marco¹,Ryan Aislin³,Hermans Cedric⁴^ORCID,Makris Michael⁵⁶^ORCID

Affiliation:

1. Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa Milan Italy

2. Department of Pathophysiology and Transplantation Università degli Studi di Milano Milan Italy

3. European Association for Hemophilia and Allied Disorders Brussels Belgium

4. Division of Haematology, Haemostasis and Thrombosis Unit, Cliniques Universitaires Saint‐Luc Université Catholique de Louvain Brussels Belgium

5. Department of Infection, Immunity and Cardiovascular Disease University of Sheffield Sheffield UK

6. Sheffield Haemophilia and Thrombosis Centre Sheffield UK

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13834

Reference36 articles.

1. The Hemophilias — From Royal Genes to Gene Therapy

2. The past and future of haemophilia: diagnosis, treatments, and its complications

3. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

4. Real-World Data on the Use of rFIXFc in Subjects With Hemophilia B for Up to 3.7 Years Demonstrates Improved Bleed Control and Adherence With Reduced Treatment Burden

5. Future of coagulation factor replacement therapy

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of joint health in patients receiving prophylaxis for haemophilia A: a cross-sectional survey in five European countries;BMJ Open;2024-09

2. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis;Orphanet Journal of Rare Diseases;2024-03-26

3. An observational study of haemophilia A patients without inhibitors using the French national claims (SNDS) database;Hematology;2024-03-06

4. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis;2023-09-06

5. Evaluation of treatment and outcome for patients with haemophilia A and haemophilia B on extended half‐life (EHL) factor products: A 12‐month data analysis;Haemophilia;2023-08-11